Dr Mark Montebello
Adjunct Senior Lecturer

Dr Mark Montebello

MB BS (UWA) FRANZCP FAChAM

Medicine & Health
National Drug & Alcohol Research Centre

Summary -

Clinical Associate Professor Mark Montebello is the Clinical Director and Senior Staff Specialist in Addiction Medicine and Psychiatry, at Drug and Alcohol Services, Northern Sydney Local Health District. He is the Accredited Medical Practitioner for the Royal North Shore Hospital Involuntary Drug and Alcohol Treatment Unit, a Honorary Senior Lecturer at the National Drug and Alcohol Research Centre, University of New South Wales, and a Clinical Associate Professor, Specialty of Addiction Medicine, Northern Clinical School, University of Sydney.

More information at https://orcid.org/0000-0002-1776-3974

Key publications 2017 to 2020 -

  1. Corbett RJ, Blakemore SK, Martin EG, Monds LA, Montebello ME. A call for concern: Frailty in middle-aged adults with alcohol use disorder. Drug and Alcohol Review (2023). DOI: 10.1111/dar.13734
  2. Black E, Bruno R, Mammen K, Mills L, Siefried KJ, Deacon RM, Shakeshaft A, Dunlop AJ, Ezard N, Montebello M, Childs S, Reid D, Holmes J, Lintzeris N. Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study. MJA (2023). http://doi.org/10.5694/mja2.52039
  3. Grover C, Monds L, Montebello M. A survey of Australian psychiatrists' and psychiatry trainees' knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders. Australasian Psychiatry (2023). 10.1177/10398562231155125
  4. Black E, Mammen K, Deacon RM, Ezard N, Mills L, Dunlop AJ, Montebello M, Reid D, Childs S, Bruno R, Shakeshaft A, Siefried KJ, Farrell M, Holmes J, Lintzeris N. Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019. Drug Alcohol Review (2023). DOI: 10.1111/dar.13588
  5. Valerio H, Conway A, Alavi M, Treloar C, Silk D, Murray C, Henderson C, Amin J, Read P, Degenhardt L, Christmass M, Montebello M, Dore G, Grebely J. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. International Journal of Drug Policy (2022). https://doi.org/10.1016/j.drugpo.2022.103876
  6. Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, McGregor I, Lintzeris N. Correlates of treatment engagement and client outcomes: Results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Substance Abuse Treatment, Prevention, and Policy (2022). https://doi.org/10.1186/s13011-022-00493-z
  7. Conway A, Valerio H, Alavi M, Silk D, Treloar C, Hajarizadeh B, Marshall AD, Martinello M, Milat A, Dunlop A, Murray C, Prain B, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Hayllar J, Reid D, Gorton C, Lam T, Christmass M, Wade A, Montebello M, Dore GJ, Grebely J. A testing campaign intervention consisting of peer-facilitated engagement, point-of-care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: the ETHOS Engage Study. Viruses (2022). https://doi.org/10.3390/v14071555
  8. Valerio H, Alavi M, Conway A, Silk D, Treloar C, Martinello M, Milat A, Dunlop A, Murray C, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Stevens A, Prain B, Hayllar J, Reid D, Montebello M, Wade A, Christmass M, Cock V, Dore GJ, Grebely J. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy (2022). https://doi.org/10.1016/j.drugpo.2022.103706
  9. Montebello M, Jefferies M, Mills L, Bruno R, Copeland J, McGregor I, Rivas C, Jackson MA, Silsbury C, Dunlop A, Lintzeris N. Mood, sleep, and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence (2022). https://doi.org/10.1016/j.drugalcdep.2022.109388
  10. Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy (2022).https://doi:10.1016/j.drugpo.2021.103492
  11. Jackson MA, Brown AL, Johnston J, Clancy R, McGregor I, Bruno R, Lintzeris N, Montebello M, Luksza J, Bowman J, Phung N, Allsop D, Dunlop AJ. The use and effects of synthetic cannabinoid receptor agonists by NSW cannabis treatment clients. Journal of Cannabis Research Vol 3, 33 (2021). https://doi.org/10.1186/s42238-021-00091-z
  12. Kwon I, Blazey A, Montebello M. The successful treatment of Kamini dependence with depot buprenorphine (Buvidal) – a case report. Australasian Psychiatry May 20 (2021). DOI: 10.1177/10398562211014214
  13. Kwon I, Montebello M, Bittoun R. Tobacco dependence management in a smoke-free inpatient drug and alcohol unit. Australasian Psychiatry Dec 10 (2020) 1-9. https://doi.org/10.1177/1039856220975287
  14. Grebely J, Read P, Cunningham E, Weltman M, Matthews G, Dunlop A, Montebello M, Martinello M, Gilliver R, Marks P, Applegate T, Dore G. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): an open-label, single-arm, phase 4, multicentre trial. Health Sci Rep (2020) 3:e151. https://doi.org/10.1002/hsr2.151
  15. Lintzeris N, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Kirby A, Montebello M, Hall M, Jefferies M, Kevin R, Bhardwaj A. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence 215 (2020) 18220. https://doi.org/10.1016/j.drugalcdep.2020.108220
  16. Mills L, Lintzeris N, Bruno R, Montebello M, Dunlop A, Deacon R, Copeland J, Jefferies M, Rivas C, Mammen K. Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review (2020). DOI: 10.1111/dar.13050

Broad Research Areas:

Drug Related Harm / Addiction, Psychiatry, Medical Education

Qualifications:
MB BS (UWA), FRANZCP, FAChAM

Specific Research Keywords:
Addiction psychiatry, addiction medicine, cannabis, amphetamines, smoking cessation

Phone
61294629011
Location
Royal North Shore Hospital Community Health Centre Level 1, 2C Herbert Street St Leonards, New South Wales, 2065 Australia
  • Journal articles | 2023
    Black E; Bruno R; Mammen K; Mills L; Siefried KJ; Deacon RM; Shakeshaft A; Dunlop AJ; Ezard N; Montebello M; Childs S; Reid D; Holmes J; Lintzeris N, 2023, 'Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study', Medical Journal of Australia, 219, pp. 218 - 226, http://dx.doi.org/10.5694/mja2.52039
    Journal articles | 2023
    Black E; Mammen K; Deacon RM; Ezard N; Mills L; Dunlop AJ; Montebello M; Reid D; Childs S; Bruno R; Shakeshaft A; Siefried KJ; Farrell M; Holmes J; Lintzeris N, 2023, 'Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019', Drug and Alcohol Review, 42, pp. 389 - 400, http://dx.doi.org/10.1111/dar.13588
    Journal articles | 2023
    Corbett RJ; Blakemore SK; Martin EG; Monds LA; Montebello ME, 2023, 'A call for concern: Frailty in middle-aged adults with alcohol use disorder', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13734
    Journal articles | 2023
    Grover C; Monds L; Montebello M, 2023, 'A survey of Australian psychiatrists’ and psychiatry trainees’ knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders', Australasian Psychiatry, 31, pp. 329 - 335, http://dx.doi.org/10.1177/10398562231155125
    Journal articles | 2022
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
    Journal articles | 2022
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J, 2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
    Journal articles | 2022
    Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L, 2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100, http://dx.doi.org/10.1016/j.drugpo.2021.103492
    Journal articles | 2022
    Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N, 2022, 'Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder', Substance Abuse: Treatment, Prevention, and Policy, 17, http://dx.doi.org/10.1186/s13011-022-00493-z
    Journal articles | 2022
    Montebello M; Jefferies M; Mills L; Bruno R; Copeland J; McGregor I; Rivas C; Jackson MA; Silsbury C; Dunlop A; Lintzeris N, 2022, 'Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial', Drug and Alcohol Dependence, 234, http://dx.doi.org/10.1016/j.drugalcdep.2022.109388
    Journal articles | 2022
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; ETHOS Engage Study Group , 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706
    Journal articles | 2022
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876
    Journal articles | 2022
    Vuong T; Gillies M; Larney S; Montebello M; Ritter A, 2022, 'The association between involuntary alcohol treatment and subsequent emergency department visits and hospitalizations: a Bayesian analysis of treated patients and matched controls', Addiction, 117, pp. 1589 - 1597, http://dx.doi.org/10.1111/add.15755
    Journal articles | 2022
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O’Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Hanson J; Marks P; Byrne M; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
    Journal articles | 2021
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J, 2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103421
    Journal articles | 2021
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ, 2021, 'The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients', Journal of Cannabis Research, 3, http://dx.doi.org/10.1186/s42238-021-00091-z
    Journal articles | 2021
    Kwon I; Blazey A; Montebello M, 2021, 'The successful treatment of Kamini dependence with depot buprenorphine (Buvidal) – a case report', Australasian Psychiatry, 29, pp. 707, http://dx.doi.org/10.1177/10398562211014214
    Journal articles | 2021
    Kwon I; Montebello M; Bittoun R, 2021, 'Tobacco dependence management in a smoke-free inpatient drug and alcohol unit', Australasian Psychiatry, 29, pp. 14 - 21, http://dx.doi.org/10.1177/1039856220975287
    Journal articles | 2020
    Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151
    Journal articles | 2020
    Lintzeris N; Mills L; Dunlop A; Copeland J; Mcgregor I; Bruno R; Kirby A; Montebello M; Hall M; Jefferies M; Kevin R; Bhardwaj A, 2020, 'Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial', Drug and Alcohol Dependence, 215, http://dx.doi.org/10.1016/j.drugalcdep.2020.108220
    Journal articles | 2020
    Mills L; Lintzeris N; Bruno R; Montebello M; Dunlop A; Deacon RM; Copeland J; Jefferies M; Rivas C; Mammen K, 2020, 'Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence', Drug and Alcohol Review, 39, pp. 356 - 364, http://dx.doi.org/10.1111/dar.13050
    Journal articles | 2019
    Jacobs NI; Montebello M; Monds LA; Lintzeris N, 2019, 'Survey of Australian psychiatrists’ and psychiatry trainees’ knowledge about and attitudes towards medicinal cannabinoids', Australasian Psychiatry, 27, pp. 80 - 85, http://dx.doi.org/10.1177/1039856218803675
    Journal articles | 2019
    Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S, 2019, 'Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia', Drug and Alcohol Review, 38, pp. 690 - 698, http://dx.doi.org/10.1111/dar.12976
    Journal articles | 2019
    Lintzeris N; Bhardwaj A; Mills L; Dunlop A; Copeland J; McGregor I; Bruno R; Gugusheff J; Phung N; Montebello M; Chan T; Kirby A; Hall M; Jefferies M; Luksza J; Shanahan M; Kevin R; Allsop D, 2019, 'Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial', JAMA Internal Medicine, 179, pp. 1242 - 1253, http://dx.doi.org/10.1001/jamainternmed.2019.1993
    Journal articles | 2018
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N; Hall M; Hazelwood S; Winmill A; Chan T; Dojcinovic R; Jago B; McKendrick L; Rivas C; Schwanz R; Yang A; Zavareh Z; Barbaro A; Black K; Ho T; Jefferies M; Jule JC; Nagubandi S; Shahidi M; Lisa Snell CS; Wijanto M, 2018, 'Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: A study protocol', BMC Psychiatry, 18, http://dx.doi.org/10.1186/s12888-018-1682-2
    Journal articles | 2018
    Lintzeris N; Monds LA; Rivas C; Leung S; Dunlop A; Newcombe D; Walters C; Galea S; White N; Montebello M; Demirkol A; Swanson N; Ali R, 2018, 'Transferring Patients from Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines', Journal of Addiction Medicine, 12, pp. 234 - 240, http://dx.doi.org/10.1097/ADM.0000000000000396
    Journal articles | 2017
    Allsop DJ; Rooney K; Arnold JC; Bhardwaj AK; Bruno R; Bartlett DJ; Montebello M; Arkell T; Richards E; Gugusheff J; Rooke S; Kerley W; Murnion B; Haber P; McGregor IS; Lintzeris N, 2017, 'Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol', Mental Health and Physical Activity, 13, pp. 57 - 67, http://dx.doi.org/10.1016/j.mhpa.2017.06.002
    Journal articles | 2015
    Montebello ME; Brett B, 2015, 'Misuse and associated harms of quetiapine and other atypical antipsychotics', Current Topics in Behavioral Neurosciences, pp. 1 - 15, http://dx.doi.org/10.1007/7854_2015_424
    Journal articles | 2014
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS, 2014, 'Nabiximols as an agonist replacement therapy during cannabis withdrawal:A randomized clinical trial', JAMA Psychiatry, 71, pp. 281 - 291, http://dx.doi.org/10.1001/jamapsychiatry.2013.3947
    Journal articles | 2014
    Bruno R; Allsop DJ; Copeland J; Lintzeris N; McGregor I; Norberg M; Dunlop A; Montebello M; Sadler C; Holland R; Rivas G, 2014, 'The impact of Sativex® on cognitive function during treatment for cannabis withdrawal', Drug and Alcohol Dependence, 140, pp. e22 - e22, http://dx.doi.org/10.1016/j.drugalcdep.2014.02.082
    Journal articles | 2013
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor I, 2013, 'A RANDOMISED CONTROLLED TRIAL OF SATIVEX (R) AS AN AGONIST REPLACEMENT THERAPY DURING CANNABIS WITHDRAWAL', DRUG AND ALCOHOL REVIEW, 32, pp. 23 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326649400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2013
    Bruno R; Allsop DJ; Copeland J; McGregor L; Norberg MM; Dunlop AJ; Montebello M; Sadler C; Holland RM; Rivas G; Muhleisen P; Booth J; Lintzeris N, 2013, 'THE IMPACT OF SATIVEX (R) ON COGNITIVE FUNCTION DURING TREATMENT FOR CANNABIS WITHDRAWAL', DRUG AND ALCOHOL REVIEW, 32, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326649400088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2013
    Montebello ME; Mendelsohn C, 2013, 'Smokers with mental illness: breaking down the myths', Medicine Today, 14, pp. 53 - 56, http://www.medicinetoday.com.au/2013/august/article/smokers-mental-illness-breaking-down-myths
    Journal articles | 2013
    Wong A; Montebello ME; Norberg MM; Rooney K; Lintzeris N; Bruno R; Booth J; Arnold JC; Mcgregor I, 2013, 'Exercise increases plasma THC concentrations in regular cannabis users', Drug and Alcohol Dependence, http://dx.doi.org/10.1016/j.drugalcdep.2013.07.031
    Journal articles | 2012
    Montebello M; Wong A; Norberg M; Lintzeris N; Mcgregor I; Arnold J, 2012, 'REINTOXICATION: CAN DIET AND EXERCISE RAISE BLOOD PLASMA Delta(9)-THC LEVELS IN LONG-TERM HEAVY CANNABIS USERS?', DRUG AND ALCOHOL REVIEW, 31, pp. 57 - 57, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700176&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2009
    Frewen AR; Baillie AJ; Montebello ME, 2009, 'Are cannabis users who participate in a randomized clinical trial different from other treatment seekers?', Journal of Substance Abuse Treatment, 36, pp. 339 - 344, http://dx.doi.org/10.1016/j.jsat.2008.07.004
    Journal articles | 2008
    Cruickshank C; Montebello ME; Dyer K; Quigley A; Blaszczyk J; Tomkins S; Shand D, 2008, 'A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal', Drug and Alcohol Review, 27, pp. 326 - 333
  • Conference Papers | 2022
    Black E; Mammen K; Deacon RM; Mills L; Montebello M; Bruno R; Dunlop AJ; Ezard N; Shakeshaft A; Farrell M; Holmes J; Reid D; Childs S; Siefried KJ; Lintzeris N, 2022, 'Clients entering New South Wales alcohol and other drug treatment services: Characteristics by principal drug of concern, July 2016-June 2019', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S31 - S32, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2022
    Mills L; Mammen K; Deacon RM; Black E; Montebello M; Bruno R; Dunlop AJ; Ezard N; Shakeshaft A; Farrell M; Holmes J; Reid D; Childs S; Siefried KJ; Lintzeris N, 2022, 'Outcomes for clients in opioid treatment programs who use amphetamine type substances: Results from a retrospective analysis of routinely-collected clinical data', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S96 - S97, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2022
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J, 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2022.103706
    Conference Posters | 2021
    Black E; Deacon RM; Mills L; Mammen K; Dunlop A; Ezard N; Montebello M; Bruno R; Shakeshaft A; Farrell M; Holmes J; Reid D; Childs S; Siefried K; Cretikos M; Lintzeris N, 2021, 'Starting treatment in public drug and alcohol services in New South Wales: What can electronic medical records tell us about amphetamine type stimulant use?', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
    Conference Papers | 2021
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Amin J; Christmass M; Dunlop AJ; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Dore GJ; Treloar C; Grebely J, 2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    Ezard N; Dunlop AJ; Liaw W; Mcdonough M; Ali R; White J; Mcketin R; Bruno R; Carr A; Gill A; Rodgers C; Montebello M; Farrell M; Heinzerling K; Haber PS; Lubman DI; Graham R; Lintzeris N, 2021, 'COVID AND THE LIMA STUDY, A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LISDEXAMFETAMINE FOR THE TREATMENT OF METHAMPHETAMINE DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S12 - S13, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    Heijstee N; Black E; Black E; Demirkol A; Mills L; Deacon RM; Mammen K; Dunlop AJ; Ezard N; Montebello M; Reid D; Childs S; Lintzeris N, 2021, 'WHO WE ARE HELPING: DESCRIBING DEMOGRAPHIC, HEALTH AND SOCIAL FACTORS ASSOCIATED WITH PRINCIPAL DRUG OF CONCERN, ALCOHOL USE AND ALCOHOL-RELATED HARMS, IN THE AUSTRALIAN ALCOHOL AND OTHER DRUG TREATMENT-SEEKING POPULATION', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S79 - S79, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    Black E; Deacon RM; Mills L; Dunlop A; Ezard N; Bruno R; Shakeshaft A; Farrell M; Holmes J; Cretikos MA; Montebello M; Reid D; Childs S; Siefried KJ; Mammen K; Lintzeris N, 2019, 'Characteristics and treatment outcomes of the drug treatment population in New South Wales: Focus on amphetamine type stimulants', in Drug and Alcohol Review, Wiley, Hobart, Australia, Vol. 38, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference, Hobart, Australia, 10 November 2019 - 13 November 2019, http://dx.doi.org/10.1111/dar.12991
    Conference Abstracts | 2019
    Black E; Deacon RM; Mills L; Dunlop AJ; Ezard N; Bruno R; Shakeshaft A; Farrell M; Holmes J; Cretikos MA; Montebello M; Reid D; Childs S; Siefried KJ; Mammen K; Lintzeris N, 2019, 'CHARACTERISTICS AND TREATMENT OUTCOMES OF THE DRUG TREATMENT POPULATION IN NEW SOUTH WALES: FOCUS ON AMPHETAMINE TYPE STIMULANTS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S27 - S28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2019
    Lintzeris N; Mills L; Dunlop AJ; Copeland J; McGregor I; Bruno R; Gugusheff J; Nghi P; Montebello M; Chan T; Kirby A; Hall M; Bhardwaj A; Jefferies M; Luksza J; Shanahan M; Kevin R; Allsop D, 2019, 'EFFICACY OF NABIXIMOLS IN REDUCING FREQUENCY OF CANNABIS USE THREE MONTHS AFTER TREATMENT CESSATION: RESULTS FROM A RANDOMISED CONTROLLED TRIAL', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S66 - S67, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Lintzeris N; Allsop D; Bhardwaj A; Mills L; Dunlop AJ; Copeland J; McGregor I; Bruno R; Gugusheff J; Phung N; Montebello M; Chan T; Kirby A; Hall M; Jefferies M; Luksza MJ; Shanahan M; Kevin R, 2018, 'FINDINGS OF A PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIAL OF NABIXIMOLS IN THE TREATMENT OF CANNABIS DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 37, pp. S45 - S46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449495000116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Lintzeris N; Allsop D; Mills L; Bhardwaj A; Dunlop AJ; Copeland J; McGregor I; Bruno R; Gugusheff J; Montebello M; Silsbury C; Jackson M; Jefferies M, 2018, 'TREATING COMORBIDITIES IN CANNABIS DEPENDENT PATIENTS WITH NABIXIMOLS: FINDINGS OF A PLACEBO CONTROLLED RANDOMISED CONTROLLED TRIAL', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 37, pp. S46 - S46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449495000117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Abstracts | 2018
    Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Bhardwaj AK; Allsop DJ; Rooney K; Arnold J; Bruno R; Montebello M; Gugusheff J; Kerley W; Murnion BP; Haber PS; McGregor IS; Lintzeris N, 2017, 'RANDOMISED CONTROLLED TRIAL OF DAILY AEROBIC EXERCISE FOR INPATIENT CANNABIS WITHDRAWAL', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2003
    Montebello ME, 2003, 'A pilot study of mirtazapine and psychotherapy in cannabis dependency', in AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, BLACKWELL PUBLISHING ASIA, pp. A2 - A2, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186635700007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

CURRENT CATEGORY 1 FUNDED RESEARCH (AND I AM ON GRANT APPLICATION)

  1. Since December 2022: Principal Investigator - Rapid Identification of Intoxication to Enable a Safer Society. ARC funded DP220103174 1/1/23-31/12/25 ($525,427). On grant application as Chief Investigator Number 4. Multisite trial led by Lauren Monds, Northern Sydney Local Health District. Additional funding from Ramsay Research and Teaching Fund Scheme 30/8/23 ($57,673.44). On grant application as Chief Investigator A.
  2. Since July 2021: Principal Investigator - ETHOS III Study - Enhancing hepatitis C testing and treatment among people who inject drugs in drug treatment settings: the ETHOS III Study. NH&MRC funded GNT2006282 1/3/22-28/2/27 ($1,349,603). On grant application as Associate Investigator. Multisite trial led by Jason Grebely, Kirby Institute.
  3. Since July 2021: Principal Investigator - A randomised controlled trial of cannabidiol (CBD) in the treatment of cannabis dependence. NH&MRC funded GNT2014980 1/7/22-31/7/26 ($2,120,137). On grant application as Associate Investigator. Multisite trial led by Nicholas Lintzeris, South Eastern Sydney Local Health District.
  4. Since July 2021: Principal Investigator - A randomised, double-blind, controlled trial of MDMA-assisted exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder. NH&MRC funded MRF2014615 1/1/22-31/12/25 ($1,951,246). On grant application as Associate Investigator. Multisite trial led by Paul Haber, Sydney Local Health District.
  5. Since June 2021: Associate Investigator - A randomised controlled trial of N-acetyl cysteine for the treatment of Alcohol Use Disorder. NH&MRC funded GNT2001375 1/7/21-30/6/25 ($1,294,923.44). On grant application as Associate Investigator. Multisite trial led by Kirsten Morley, Sydney Local Health District.
  6. Since January 2014: Associate Investigator - Randomised double-blind placebo-controlled study of lisdexamphetamine for the treatment of methamphetamine dependence. NH&MRC funded GNT1109466 1/1/16-31/12/21 ($1,303,735.21). On grant application as Associate Investigator. Multisite trial with NDARC, St Vincent’s Hospital Sydney, Hunter New England Local Health District, Western Sydney Local Health District, Drug and Alcohol Services South Australia, National Drug Research Institute.

 

 

COMPLETED CATEGORY 1 FUNDED RESEARCH (AND I AM ON GRANT APPLICATION)

  1. 2014-2017: Associate Investigator - An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients. NH&MRC funded GNT1088902 1/1/15-31/12/17 ($762,711.30). On grant application as Associate Investigator. Collaboration partners - NDARC, Sydney University, Hunter New England Local Health District, Western Sydney Local Health District.

  1. November 2021: Nominated for the NSLHD MHDA Manager of the Year Award
  2. June 2021: Winner of the NSLHD Quality and Research Awards – Keeping People Healthy award category, for Tobacco Dependence Management in a Smoke-Free Inpatient Drug and Alcohol Service
  3. November 2019: Winner of the Australasian Professional Society on Alcohol and other Drugs (APSAD) Clinician of the Year Award
  4. September 2019: Nominated for the 2019 RANZCP NSW Meritorious Service Award
  5. December 2018: Winner of the Journal of Addiction Medicine Most Downloaded Article Published in 2018 for “Transferring Patients from Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines.”
  6. November 2018: Nominated for the Australasian Professional Society on Alcohol and other Drugs (APSAD) Mentor of the Year Award
  7. 1991: Winner of the Neuromuscular Disease Research Institute Medical Student Neuropathology Prize
  8. 1988: Winner of the Ralph Pervan Scholarship, Currie Hall at the University of Western Australia

CURRENT OTHER RESEARCH

  1. Since October 2023: Principal Investigator - The COQI Cohort Study - Examining clinical outcomes and quality indicators for clients attending NSW AOD treatment services Aboriginal clients. Multisite trial led by Nicholas Lintzeris, South Eastern Sydney Local Health District. NSW Health funded.
  2. Since August 2023: Explore the strategies for facilitating oral healthcare for clients in Opioid Treatment Program: A Qualitative Study. Led by Grace Wong, Northern Sydney Local Health District.
  3. Since February 2023: Oral Healthcare of Opioid Treatment Program. Led by Grace Wong, Northern Sydney Local Health District.
  4. Since November 2022: Principal Investigator - ATS Use Among Clients in OAT: A Qualitative Study of Consumer and Clinician Perspectives. Multisite trial led by Llew Mills, South Eastern Sydney Local Health District.
  5. Since November 2021: Associate Investigator - Substance Use and Mental Health in Young People: Evaluating the Specialist Addiction Service for Adolescents (SASA). Led by David Gordon, Northern Sydney Local Health District and Belinda Volkow, Sydney Drug Education and Counselling Centre.
  6. Since September 2021: Principal Investigator - An observational cohort study to evaluate the use of finger-stick point-of-care hepatitis C RNA testing to enhance diagnosis and treatment of hepatitis C virus infection among people at risk of HCV infection: The National Australian HCV Point-of-Care Testing Program. NH&MRC funded APP2013921 ($1,498,086), Gilead ($711,716), Commonwealth Department of Health ($6,500,000). I am not on the grant application. Multisite trial led by Jason Grebely, Kirby Institute.
  7. Since May 2021: Associate Investigator - Drug Intoxication Detection Film Study. Led by Barry Renner, Northern Sydney Local Health District.
  8. Since March 2021: Associate Investigator - The feasibility of using mobile gaming applications (Graze Invaders) as a means of assessing cognition in Opioid Treatment Program (OTP) clients. Led by Angelica Wong, Northern Sydney Local Health District.
  9. Since February 2021: Associate Investigator - Micro-dosing with buprenorphine to transfer from methadone to buprenorphine - a prospective single-arm, phase 2 clinical trial. Multisite trial led by Chris Tremonti, Sydney Local Health District.
  10. Since January 2021: Principal Investigator - Investigating memory reliability in intoxicated victims and witnesses of crime. Led by Lauren Monds, Northern Sydney Local Health District.
  11. Since February 2020: Principal Investigator - Alcohol and Other Drugs (AOD) client concerns and wishes regarding cognitive impairment treatment. Multisite trial led by Lauren Monds, South Eastern Sydney Local Health District / Northern Sydney Local Health District / University of Sydney.
  12. Since October 2019: Associate Investigator - DBS HIV Testing Pilot - NSW Dried Blood Spot Self-Sampling HIV and Hepatitis C Testing Pilot Program. Multisite trial led by Dr Anna McNulty, South Eastern Sydney Local Health District. NSW Health funded.
  13. Since September 2019: Principal Investigator - The COQI Cohort Study - Examining clinical outcomes and quality indicators for clients attending NSW public alcohol and other drug (AOD) treatment services. Multisite trial led by Nicholas Lintzeris, South Eastern Sydney Local Health District. NSW Health funded.
  14. Since December 2018: Principal Investigator - Defining the clinical role of topiramate in the treatment of alcohol dependence in Australia. NH&MRC funded ($718,836). I am not on the grant application. Multisite trial led by Paul Haber, Sydney Local Health District.
  15. Since December 2018: Principal Investigator - CoLAB - An open-label, multicentre, single-arm trial of monthly injections of extended-release buprenorphine in people with opioid dependence. Indivior funded ($1,814,536 and study medication). Multisite trial led by Michael Farrell, National Drug and Alcohol Research Centre.
  16. Since May 2018: Principal Investigator - ETHOS ENGAGE Study - A non-randomized trial to assess the effect of an intervention incorporating on-site hepatitis C virus RNA testing, liver fibrosis assessment, and linkage to care to enhance scale-up of direct-acting antiviral therapy for hepatitis C virus infection among people with a history of injecting drug use, and either recent injecting drug use or receiving opioid substitution therapy. Multisite trial led by Jason Grebely, Kirby Institute.